Group 1: Innovative Drug Sector - The innovative drug concept stocks have generally risen, with notable increases in companies such as CSPC Pharmaceutical Group (up 6.34%), WuXi Biologics (up 5.54%), and Innovent Biologics (up 5.15%) due to significant collaborations announced in early 2026, including a $18.5 billion partnership between CSPC and AstraZeneca [1] - Junshi Biosciences has seen a rise of over 9%, with a cumulative increase of over 24% this month, following an exclusive commercialization agreement for its PD-1 antibody in Japan [1] - Baijie Pharmaceutical has surged over 10%, with its stock price increasing more than 440% from its IPO price of HKD 26.38 [1] Group 2: AI and Technology Sector - Yunzhisheng has increased by over 9%, supported by a report highlighting its strong industry barriers and partnerships with top hospitals, covering 40% of the top 100 hospitals in China [2] - Wanka Yilian has risen over 10%, with a year-to-date increase of over 90%, following Alibaba's announcement of its AI strategy transition [2] Group 3: CRO Sector - CRO concept stocks have shown strong performance, with companies like Vyaire Medical (up 6.14%) and WuXi Biologics (up 5.54%) leading the gains, as projections indicate a significant increase in net profits for WuXi AppTec and Tigermed in 2025 [2] - The global biopharmaceutical investment data is expected to recover in 2025, with a projected growth rate of 2.7% globally and 6.4% in China, driven by a hot market for innovative drug development [2] Group 4: Film and Entertainment Sector - Film concept stocks have risen, with companies like Damai Entertainment (up 8.16%) and Maoyan Entertainment (up 4.8%) benefiting from the pre-sale of new films for the 2026 Spring Festival [3] Group 5: Financial Performance and Forecasts - China National Nuclear Corporation International has seen a nearly 14% increase, with a forecasted revenue of at least CNY 2.46 billion for 2025, representing a year-on-year growth of at least 33.6% [3] - Pop Mart has increased by over 4.5%, with a projection of over 400 million global sales of its products in 2025 [4] Group 6: US Market Highlights - In the US market, companies like Lexin (up 8.54%) and Credo Technology (up 10.78%) have shown strong performance, driven by positive market conditions and significant agreements [5] - STMicroelectronics has risen by 8.91% following a multi-billion dollar agreement with Amazon to advance semiconductor technology [5] - Li Auto has seen a decline of 3.27% after a downgrade from Morgan Stanley, reflecting concerns about the Chinese automotive market's performance in 2026 [6]

截至2026年2月10日 10:49，恒生港股通创新药指数(HSSCID)强势上涨4.32%，港股通创新药ETF易方达 (159316)上涨3.50%， 冲击3连涨。盘中换手9.42%，成交4.03亿元。 港股通创新药ETF易方达(159316)紧密跟踪恒生港股通创新药指数，恒生港股通创新药指数旨在反映可 经港股通买卖，业务与创新药研究、开发及生产相关的香港上市公司之表现。 相关产品 根据合作协议，信达生物依托自身成熟的抗体技术平台及高效的临床能力，将主导相关项目从药物发现 至中国临床概念验证（二期临床试验完成）的研发工作。根据协议，礼来获得相关项目在大中华区以外 的全球独家开发与商业化许可，信达生物保留相关项目在大中华区的全部权利。根据协议条款，信达生 物将获得 3.5 亿美元首付款；在达成后续特定里程碑事件后，信达生物还有资格获得总额最高约85亿美 元的研发、监管及商业化里程碑付款。此外，信达生物有权就各产品在大中华区以外的净销售额获得梯 度的销售分成。 中邮证券认为，创新药板块虽短期受资金面扰动有所回调，但产业层面全球参与度提升趋势已在2025年 充分体现；国产新药正从早研追赶迈向效率制胜阶段，中期维度 ...

Group 1 - CRO concept stocks have shown significant gains, with Weiya Bio rising by 6.14% to HKD 2.42, WuXi Biologics increasing by 6.01% to HKD 40.54, Tigermed up by 4.65% to HKD 56.3, and WuXi AppTec rising by 4.31% to HKD 121 [1] - WuXi AppTec's net profit is expected to increase by 103% year-on-year in 2025, while Tigermed's net profit is projected to grow by 105-204% [1] - Global biopharmaceutical investment and financing data is expected to recover starting in 2025, with global and China year-on-year growth rates of 2.7% and 6.4% respectively, driven by a surge in innovative drug development [1] Group 2 - The report from Guotai Junan Securities indicates that as financing and business development (BD) recover, pharmaceutical companies are increasing their investment in clinical trials, leading to a resurgence in demand for clinical CRO, SMO, and registration services [1] - Debon Securities believes that the CXO and upstream research services primarily support the development and later production of innovative drugs, and expects both sectors to maintain a positive performance trend as innovative drug development heats up [1]

Core Insights - The Hong Kong stock market for innovative drugs is experiencing a strong rally, with the Hong Kong Stock Connect Innovative Drug ETF (159570) rising over 3% and achieving a trading volume exceeding 1.3 billion yuan yesterday and over 1 billion yuan today, bringing its total size to over 25 billion yuan [1][3]. Group 1: Market Performance - The innovative drug sector has seen significant interest, with the ETF's latest scale leading among its peers [1]. - Notable stocks within the ETF, such as Rongchang Biopharmaceutical and Zai Lab, have reported gains exceeding 6%, while others like Innovent Biologics and CSPC Pharmaceutical have also shown strong performance [4][5]. Group 2: Recent Developments - Recent collaborations in the innovative drug sector include a partnership between Fuhong Hanlin and Eisai for the commercialization of the anti-PD-1 monoclonal antibody, with an upfront payment of $75 million and potential milestone payments totaling up to $300 million [3]. - Yunding Xinyao announced the approval of Etrasimod for the treatment of moderate to severe active ulcerative colitis in China, following a $224 million deal for exclusive rights in Greater China and South Korea [3]. - Innovent Biologics has entered a strategic collaboration with Eli Lilly to advance global R&D in oncology and immunology, with an upfront payment of $350 million and potential milestone payments of up to $8.5 billion [3]. Group 3: Analyst Recommendations - Analysts from Kaiyuan Securities suggest increasing allocation to the innovative drug sector, highlighting the valuation attractiveness of quality stocks and the potential for significant returns from companies with strong clinical data and overseas expansion prospects [4]. - The report emphasizes the importance of focusing on innovative drugs that have shown resilience and potential for growth, particularly in the context of upcoming earnings reports in 2025 and early 2026 [6].

Group 1 - The core viewpoint of the news is that Wanbangde (SZ002082) experienced a significant stock price increase, reaching a limit up of 10% on February 10, 2026, with a total market capitalization of 11.371 billion yuan and a circulating market value of 10.285 billion yuan [1][2]. Group 2 - Wanbangde has made several breakthroughs in innovative drug research, including the completion of II/III phase clinical enrollment for Alzheimer's disease medication and FDA orphan drug designation for ALS medication, indicating strong R&D capabilities [2]. - The company’s project on Shisuanjianma controlled-release tablets has been included in a national major science and technology project, receiving national-level recognition, which highlights its technical strength [2]. - The therapeutic areas of Alzheimer's disease and ALS have significant unmet clinical needs, suggesting a large market potential for its products [2]. - Wanbangde has established strategic collaborations with companies like Haixiang Pharmaceutical and over 50 research institutions, enhancing its support and synergy in pharmaceutical R&D [2]. - The company has secured a 10-year exclusive import right to enter an 8.3 billion yuan erectile dysfunction market, with globally unique dosage forms providing a competitive advantage [2]. - The pharmaceutical sector, particularly innovative drug concepts, has garnered market attention recently, with active stock performance from companies achieving R&D breakthroughs [2]. - On February 10, there was a capital inflow into the pharmaceutical sector, contributing to Wanbangde's limit-up performance, indicating a certain level of sectoral linkage [2]. - Technical indicators for the stock, such as the MACD, may form a golden cross, attracting interest from technical investors [2].

Group 1 - The stock of Haixiang Pharmaceutical has achieved a three-day limit-up, indicating strong market interest and performance [1] - The stock reached a trading limit at 10:11 AM with a transaction volume of 1.309 billion yuan and a turnover rate of 9.44% [1] - The company operates in the pharmaceutical and dye industries, with a fully integrated production chain for its main products [1] Group 2 - In the dye sector, Haixiang's leading products, such as the active blue KN-R series, have been recognized with the National Manufacturing Single Champion title [1] - In the innovative drug sector, the company has invested in multiple projects, including vaccines for HPV infection and liver cancer, with some projects already in clinical stages [1] - In the active pharmaceutical ingredient sector, Haixiang leads global market share with products like clindamycin and meropenem, maintaining long-term collaborations with major pharmaceutical companies like Pfizer and BI [1]

（2）创新药方面，2~3月为港股药企业绩披露窗口，多家有望迎来减亏或扭亏；展望全年，AACR(4 月)、ASCO(5月)、ESMO(10月)等学术会议渐次到来，国产创新药有望进一步带来临床数据的兑现。 关注港股通科技ETF基金（159101.SZ）及其联接C（025806.OF），被动跟踪国证港股通科技指数，该 指数在恒生科技基础上，龙头权重更集中（阿里巴巴、腾讯控股合计占比30%），同时兼顾创新药龙头 （药明生物/信达生物/康方生物）。港股通科技ETF基金（159101.SZ）在深圳证券交易所上市，并支持 T+0日内灵活回转交易，为A股投资者提供低门槛、免开跨境户和免换汇的便利。 2月10日盘初，港股AI应用、创新药板块延续昨日涨势。阅文集团、智谱涨超6%，快手-W涨超4%，药 明生物、康方生物、信达生物涨超2%，港股通科技ETF基金（159101.SZ）盘中涨1%。 综合招商证券、国金证券等机构观点，港股科技资产前期回调较为充分，后市催化增多： （1）AI应用方面，腾讯、阿里纷纷在春节期间进行大模型宣传、快手可灵年化ARR超预期、DeepSeek 或在春节期间发布最新V4大模型。 ...

Core Viewpoint - The Hong Kong stock market showed strong performance in the early session, particularly in the innovative drug sector, indicating a robust demand for pharmaceuticals and a shift towards an "innovation-driven" revenue era in the industry [1] Group 1: Market Performance - Innovative drug stocks performed well, with notable gains: Zai Lab rose over 6%, CanSino Biologics-B increased over 5%, and Rongchang Biologics climbed over 4% [1] - The Hong Kong Innovative Drug ETF (159567) rose over 2%, reflecting the positive sentiment in the sector [1] Group 2: Industry Insights - Analysts attribute the pharmaceutical industry's ability to reach new highs despite ongoing challenges to the continuous demand for medical solutions and the increasing number of unmet needs [1] - Pharmaceutical companies are significantly increasing their R&D investments to address these unmet needs, positioning China as a key player in global innovative drug development [1] - The trend of overseas licensing has been rising year after year, further emphasizing the industry's shift towards innovation [1] Group 3: Investment Opportunities - The Hong Kong Innovative Drug ETF (159567) tracks the National Index of Hong Kong Innovative Drugs, aiming to reflect the performance characteristics of listed companies in the innovative drug sector [1] - Investors can also access the Hong Kong Innovative Drug ETF through linked funds (Class A: 023929, Class C: 023930) to capitalize on the upward opportunities in the sector [1]

Group 1 - The Hong Kong Innovative Drug ETF (513120) increased by 1.03% on February 9, with a trading volume of 3.646 billion yuan [1] - The fund's shares decreased by 36.5 million, bringing the total shares to 20.21 billion, with an increase of 982 million shares over the last 20 trading days [1] - The latest net asset value of the fund is 25.98 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Innovative Drug ETF is the return rate of the CSI Hong Kong Innovative Drug Index (denominated in RMB) [1] - The fund is managed by Guangfa Fund Management Co., Ltd., with Liu Jie as the fund manager [1] - Since its establishment on July 1, 2022, the fund has returned 28.54%, while the return over the past month is -5.38% [1]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector, emphasizing the potential for investment in bottom assets within the industry [5]. Core Insights - The report highlights the ongoing opportunities in the pharmaceutical sector, particularly in areas such as AI in medicine and innovative drug developments, while noting the recent market performance where the pharmaceutical sector outperformed the broader market [11][26]. - It emphasizes the importance of monitoring key milestones and data updates from major conferences in 2026, such as AACR and ASCO, which could significantly impact investment decisions [11]. Summary by Sections Market Performance - The pharmaceutical sector has shown a return of 3.28% since the beginning of 2026, outperforming the Shanghai Composite Index by 2.99 percentage points [26]. - Recent weekly performance indicates a slight increase in the pharmaceutical sector by 0.14%, while the broader market declined by 1.33% [11][26]. Investment Opportunities - The report identifies several key areas for investment, including: - IO plus strategies involving VEGF dual antibodies, which are gaining traction in clinical trials [12]. - ADC (Antibody-Drug Conjugates) with a focus on large indications and new indications that could enhance overseas mapping [14]. - The development of new RAS inhibitors and their potential in treating various cancers, highlighting companies like 加科思 and 劲方生物 [15]. - The commercial potential of CDK4/6 inhibitors in HR+ breast cancer, particularly as patents expire [16]. Key Companies and Recommendations - The report recommends several companies for investment, including: - 药明生物, 泰格医药, 先声药业, 康弘药业, 普洛药业, 美好医疗, 迪安诊断, 和铂医药-B, 药石科技, and 天宇股份, all of which are expected to perform well in the current market environment [8][19]. - It notes that the pharmaceutical sector's current valuation is 22.8 times PE based on 2026 earnings forecasts, indicating a premium over the broader A-share market [30]. Clinical Developments - The report discusses various clinical trials and their implications, such as: - The anticipated data readouts for several ADCs and dual antibodies in 2026, which could significantly influence market dynamics [17][20]. - The ongoing advancements in small nucleic acids and their expected commercialization, which could lead to substantial market growth [19][23]. Regulatory Environment - The report highlights the regulatory landscape, noting that the National Medical Insurance Administration will intensify oversight in 2026, which may impact pharmaceutical companies [22]. Overall Sector Outlook - The report maintains a positive outlook on the pharmaceutical sector, suggesting that despite recent market fluctuations, there are significant opportunities for growth and investment, particularly in innovative therapies and technologies [11][19].